A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

  • Cancer
  • Breast Cancer
  • Breast Cancer HER-2 Positive
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Countries
  • Algeria
  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • China
  • Ecuador
  • Egypt
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Israel
  • Italy
  • Lebanon
  • Lithuania
  • Mexico
  • Morocco
  • Netherlands
  • pakistan
  • Peru
  • Poland
  • Portugal
  • Saudi Arabia
  • Serbia
  • Slovenia
  • Spain
  • Sweden
  • Turkey
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • Uruguay
  • venezuela
Trial Identifier:

NCT01572038 2011-005334-20 MO28047

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line treatment in participants with metastatic or locally recurrent HER2-positive breast cancer. Participants will receive pertuzumab intravenously (IV) and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT01572038,MO28047,2011-005334-20 Trial Identifier
      Docetaxel, Nab-paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab Treatments
      Breast Neoplasms Condition
      Official Title

      A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection
      • HER2-positive breast cancer
      • Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2
      • LVEF of at least 50 percent (%)
      Exclusion Criteria
      • Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease
      • Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (</=) 6 months
      • Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
      • Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting
      • History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
      • Central nervous system (CNS) metastases
      • Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)
      • History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
      • Inadequate bone marrow, liver or renal function
      • Uncontrolled hypertension
      • Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on ForPatients in related disease areas.

      Breast Cancer HER-2 Positive

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now